Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 5/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429482 | 0.95 | CYP3A4 (0.38) | CYP3A4ELANEKCNH2IRAK4CTSB | |
| SCHEMBL4294855 | 0.86 | DNMT1 (0.34) | ELANEKCNH2CTSB | |
| SCHEMBL2429485 | 0.85 | CYP3A4 (0.33) | CYP3A4ELANEKCNH2IRAK4KDM4E | |
| SCHEMBL3624949 | 0.84 | CYP3A4 (0.40) | CYP3A4ELANEKCNH2IRAK4CTSB | |
| SCHEMBL2426758 | 0.82 | DNMT1 (0.34) | ELANEKCNH2CTSBTDP1 | |
| SCHEMBL4297033 | 0.79 | STING1 (0.38) | CYP3A4IRAK4 | |
| SCHEMBL4565058 | 0.79 | MMP2 (0.38) | CYP3A4IRAK4 | |
| SCHEMBL8195028 | 0.78 | CYP3A4 (0.36) | CYP3A4ELANEKCNH2IRAK4KDM4E | |
| SCHEMBL733229 | 0.78 | CYP3A4 (0.39) | CYP3A4ELANEKCNH2CTSB | |
| SCHEMBL3618649 | 0.76 | CYP3A4 (0.40) | CYP3A4ELANEKCNH2IRAK4CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314062-B2 | Macrocyclic compounds as antiviral agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2012-11-20 | — | — | US | disclosed |
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312241-A1 | Macrocyclic Compounds as Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | CYP3A4 338/4885ELANE 1857/4885KCNH2 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.